The application of F127ZIF‐8AB680 in EGFR‐mutant NSCLC represents an innovative approach to overcome the limitations of current CD73 inhibitors, whose effects are compromised by poor tumor penetration and rapid clearance from the body. This evidence concerns the gene EGFR and non-small cell lung carcinoma.